Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Cannabis: Medical Treatments

Department of Health and Social Care written question – answered on 24th January 2020.

Alert me about debates like this

Photo of Crispin Blunt Crispin Blunt Conservative, Reigate

To ask the Secretary of State for Health and Social Care, whether there are circumstances under which Specialist Importers of cannabis-based products for medicinal use are permitted to import that product in bulk.

Photo of Crispin Blunt Crispin Blunt Conservative, Reigate

To ask the Secretary of State for Health and Social Care, how many notifications the Medicines and Healthcare products Regulatory Agency has received from (a) pharmacies and (b) Specialist Importers on importation orders for unlicensed cannabis-based products for medicinal use in the last 12 months.

Photo of Crispin Blunt Crispin Blunt Conservative, Reigate

To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency has assessed the (a) safety and (b) quality of unlicensed cannabis-based products for medicinal use.

Photo of Crispin Blunt Crispin Blunt Conservative, Reigate

To ask the Secretary of State for Health and Social Care, whether there are circumstances under which Specialist Importers may import cannabis-based active pharmaceutical ingredients for use in the manufacturing of cannabis-based products for medicinal use in the UK.

Photo of Jo Churchill Jo Churchill The Parliamentary Under-Secretary for Health and Social Care

Unlicensed cannabis-based products for medicinal use (CBPM) may only be imported to meet the special clinical need of individual patients. It is not currently possible to import bulk quantities of these products. This restriction forms part of the checks and balances that the Advisory Council on the Misuse of Drugs asked the Government to put in place when rescheduling CBPMs to minimise the risk of misuse and diversion.

The Medicines and Healthcare products and Regulatory Agency has received 242 notifications for the importation of unlicensed CBPMs from specialist importers in the past 12 months.

Unlicensed medicines, including CBPMs are not assessed by the MHRA for quality, safety and efficacy, but must be notified to the MHRA prior to import and meet basic production standards.

Importers registered with the MHRA can import active pharmaceutical ingredients where intended for the production of a medicinal product for use in humans.

Does this answer the above question?

Yes2 people think so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.